Genitourinary Cancers — An Interview with Dr William K Oh on Recent Trial Updates
Research To Practice | Oncology Videos · Dr. Neil Love
April 23, 202544m 21s
Audio is streamed directly from the publisher (traffic.libsyn.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Featuring an interview with Dr William K Oh, including the following topics:
- Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00)
- Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10)
- Radiopharmaceuticals for the treatment of mCRPC (16:53)
- Available data on cabozantinib for mCRPC (24:38)
- Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17)
- Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00)
- Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28)
- Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39)
- Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44)
- Data surrounding adjuvant immunotherapy for MIBC (38:07)
- Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44)
- Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06)
- Implementation of emerging data in the treatment landscape of UC (41:56)